Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Safety
  4. Fast Track Articles
  5. Fast Track Article
image of Efficacy and Safety Profile of Suvorexant for the Treatment of Insomnia

Abstract

Insomnia is becoming a concern in general practice as it affects around 30% of adults. It is a sleep disorder characterized by trouble getting asleep, staying asleep, waking up early, and difficulty falling back to sleep. The most commonly used hypnotics, such as benzodiazepines, Z drugs, etc, are associated with various issues, including psychomotor and cognitive impairment. Dual orexin receptor antagonists are an emerging class of hypnotics used to treat insomnia. Suvorexant is a first-in-class dual orexin receptor antagonist approved by the US FDA in 2014 for the treatment of insomnia. Suvorexant is administered orally, absorbed well, metabolized by cytochrome P450 enzyme, and excreted through feces. Some common adverse effects of suvorexant are headache, somnolence, dizziness, diarrhea, cough, abnormal dreams, and upper respiratory tract infection. The current paper aimed to review the pharmacokinetics and pharmacodynamic properties of suvorexant.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863337982250212111648
2025-03-03
2025-03-28

  • From This Site

    /content/journals/cds/10.2174/0115748863337982250212111648
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Roth T. Insomnia: Definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 2007 3 5 Suppl. S7 S10 17824495
    [Google Scholar]
  2. Dopheide J.A. Insomnia overview: Epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am. J. Manag. Care 2020 26 4 Suppl. S76 S84 32282177
    [Google Scholar]
  3. Ohayon M.M. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med. Rev. 2002 6 2 97 111 10.1053/smrv.2002.0186 12531146
    [Google Scholar]
  4. Soldatos C.R. Allaert F.A. Ohta T. Dikeos D.G. How do individuals sleep around the world? Results from a single-day survey in ten countries. Sleep Med. 2005 6 1 5 13 10.1016/j.sleep.2004.10.006 15680289
    [Google Scholar]
  5. Leger D. Poursain B. An international survey of insomnia: Under-recognition and under-treatment of a polysymptomatic condition. Curr. Med. Res. Opin. 2005 21 11 1785 1792 10.1185/030079905X65637 16307699
    [Google Scholar]
  6. Dregan A. Armstrong D. Cross-country variation in sleep disturbance among working and older age groups: An analysis based on the European Social Survey. Int. Psychogeriatr. 2011 23 9 1413 1420 10.1017/S1041610211000664 21554795
    [Google Scholar]
  7. Léger D. Poursain B. Neubauer D. Uchiyama M. An international survey of sleeping problems in the general population. Curr. Med. Res. Opin. 2008 24 1 307 317 10.1185/030079907X253771 18070379
    [Google Scholar]
  8. Morin C.M. Jarrin D.C. Epidemiology of insomnia. Sleep Med. Clin. 2022 17 2 173 191 10.1016/j.jsmc.2022.03.003 35659072
    [Google Scholar]
  9. Zhang L. Deng Y. Hui R. Tang Y. Yu S. Li Y. Hu Y. Li N. The effects of acupuncture on clinical efficacy and steady-state visual evoked potentials in insomnia patients with emotional disorders: A randomized single-blind sham-controlled trial. Front. Neurol. 2023 13 1053642 10.3389/fneur.2022.1053642 36742043
    [Google Scholar]
  10. Pentagna Á Castro LH Conway BA What’s new in insomnia? Diagnosis and treatment. Arqu. Neuro Psiquiat. 2022 80 S 05 307 312 10.1590/0004‑282x‑anp‑2022‑s124
    [Google Scholar]
  11. Glass J. Lanctôt K.L. Herrmann N. Sproule B.A. Busto U.E. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 2005 331 7526 1169 10.1136/bmj.38623.768588.47 16284208
    [Google Scholar]
  12. Schroeck J.L. Ford J. Conway E.L. Kurtzhalts K.E. Gee M.E. Vollmer K.A. Mergenhagen K.A. Review of safety and efficacy of sleep medicines in older adults. Clin. Ther. 2016 38 11 2340 2372 10.1016/j.clinthera.2016.09.010 27751669
    [Google Scholar]
  13. Jordan A.S. O’Donoghue F.J. Cori J.M. Trinder J. Physiology of arousal in obstructive sleep apnea and potential impacts for sedative treatment. Am. J. Respir. Crit. Care Med. 2017 196 7 814 821 10.1164/rccm.201612‑2511PP 28399379
    [Google Scholar]
  14. Mason M Cates CJ Smith I Effects of opioid, hypnotic and sedating medications on sleep‐disordered breathing in adults with obstructive sleep apnoea. Cochrane. Database Syst. Rev. 2015 14 7 CD011090 10.1002/14651858.CD011090.pub2
    [Google Scholar]
  15. Lyphout C. Yates C. Margolin Z.R. Dargan P.I. Dines A.M. Heyerdahl F. Hovda K.E. Giraudon I. Bucher-Bartelson B. Green J.L. Wood D.M. Euro-DEN Research Group Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: Profiling and relation to sales data. Eur. J. Clin. Pharmacol. 2019 75 1 77 85 10.1007/s00228‑018‑2550‑1 30244371
    [Google Scholar]
  16. Bennett T. Bray D. Neville M.W. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. P T 2014 39 4 264 266 24757363
    [Google Scholar]
  17. Michelson D. Snyder E. Paradis E. Chengan-Liu M. Snavely D.B. Hutzelmann J. Walsh J.K. Krystal A.D. Benca R.M. Cohn M. Lines C. Roth T. Herring W.J. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 13 5 461 471 10.1016/S1474‑4422(14)70053‑5 24680372
    [Google Scholar]
  18. Herring W.J. Snyder E. Budd K. Hutzelmann J. Snavely D. Liu K. Lines C. Roth T. Michelson D. Orexin receptor antagonism for treatment of insomnia. Neurology 2012 79 23 2265 2274 10.1212/WNL.0b013e31827688ee 23197752
    [Google Scholar]
  19. Efficacy of suvorexant to treat insomnia related to bipolar disorder. 2012 Available from: https://med.stanford.edu/mosslab/research/_jcr_content/main/clinicaltrials.html?ctid=NCT02527564&conditionId=&serviceLineId=&condition=&alpha=e
  20. A study of suvorexant in patients with multiple sclerosis fatigue and insomnia. 2012 Available from: https://ctv.veeva.com/study/a-study-of-suvorexant-in-patients-with-multiple-sclerosis-fatigue-and-insomnia
  21. Drake C.L. Kalmbach D.A. Cheng P. Roth T. Tran K.M. Cuamatzi-Castelan A. Atkinson R. Singh M. Tonnu C.V. Fellman-Couture C. Can the orexin antagonist suvorexant preserve the ability to awaken to auditory stimuli while improving sleep? J. Clin. Sleep Med. 2019 15 9 1285 1291 10.5664/jcsm.7920 31538599
    [Google Scholar]
  22. Herring W.J. Ceesay P. Snyder E. Bliwise D. Budd K. Hutzelmann J. Stevens J. Lines C. Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: A randomized trial. Alzheimers Dement. 2020 16 3 541 551 10.1002/alz.12035 31944580
    [Google Scholar]
  23. A pilot study of suvorexant for insomnia in parkinson disease. 2012 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5406960/
  24. Sutton E. Profile of suvorexant in the management of insomnia. Drug Des. Devel. Ther. 2015 9 6035 6042 10.2147/DDDT.S73224 26648692
    [Google Scholar]
  25. Cox C.D. Breslin M.J. Whitman D.B. Schreier J.D. McGaughey G.B. Bogusky M.J. Roecker A.J. Mercer S.P. Bednar R.A. Lemaire W. Bruno J.G. Reiss D.R. Harrell C.M. Murphy K.L. Garson S.L. Doran S.M. Prueksaritanont T. Anderson W.B. Tang C. Roller S. Cabalu T.D. Cui D. Hartman G.D. Young S.D. Koblan K.S. Winrow C.J. Renger J.J. Coleman P.J. Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia. J. Med. Chem. 2010 53 14 5320 5332 10.1021/jm100541c 20565075
    [Google Scholar]
  26. Preskorn S.H. CNS drug development: Lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I. J. Psychiatr. Pract. 2014 20 6 460 465 10.1097/01.pra.0000456594.66363.6f 25406050
    [Google Scholar]
  27. Citrome L. Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 2014 68 12 1429 1441 10.1111/ijcp.12568 25231363
    [Google Scholar]
  28. Anderson S. Norman J. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant. Nat. Sci. Sleep 2016 8 239 247 10.2147/NSS.S76910 27471419
    [Google Scholar]
  29. Lee-Iannotti J.K. Parish J.M. Suvorexant: A promising, novel treatment for insomnia. Neuropsychiatr. Dis. Treat. 2016 12 491 495 26955275
    [Google Scholar]
  30. Berger A.A. Sottosanti E.R. Winnick A. Keefe J. Gilbert E. Hasoon J. Thase M.E. Kaye A.D. Viswanath O. Urits I. Suvorexant in the treatment of difficulty falling and staying asleep (insomnia). Psychopharmacol. Bull. 2022 52 1 68 90 35342199
    [Google Scholar]
  31. Dubey A.K. Handu S.S. Mediratta P.K. Suvorexant: The first orexin receptor antagonist to treat insomnia. J. Pharmacol. Pharmacother. 2015 6 2 118 121 10.4103/0976‑500X.155496 25969666
    [Google Scholar]
  32. Neubauer D.N. Insomnia pharmacotherapies: Pharmacodynamics, strategies, new directions, and key measures in clinical trials. Handb. Behav. Neurosci. 2019 30 639 648 10.1016/B978‑0‑12‑813743‑7.00042‑6
    [Google Scholar]
  33. Efficacy of suvorexant on post-operative sleep disturbance. 2012 Available from: https://clinicaltrial.be/en/details/265635?per_page=100&only_recruiting=0&only_eligible=0
  34. Efficacy of suvorexant in the treatment of insomnia in midlife women with pre-diabetes. 2012 Available from: https://ctv.veeva.com/study/efficacy-of-suvorexant-in-the-treatment-of-insomnia-in-midlife-women-with-pre-diabetes
  35. Double-blind randomized controlled trial comparing suvorexant 20 mg to placebo for treatment of insomnia in cancer survivors. 2012 Available from: https://connect.careboxhealth.com/en-US/trial/listing/442816
  36. Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes. 2012 Available from: https://www.centerwatch.com/clinical-trials/listings/NCT05908526/insomnia-treatment-and-ema-ecological-momentary-assessment-outcomes?id=189&slug=insomnia
  37. Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl. 2012 Available from: https://go.drugbank.com/conditions/DBCOND0144416
  38. Suvorexant and Sleep/Delirium in ICU Patients. 2012 Available from: https://www.sciencedirect.com/science/article/abs/pii/S0883944120305645#:~:text=Sleep%20disturbances%20can%20be%20a,or%20in%20combination%20with%20ramelteon.
  39. Sun H. Yee K.L. Gill S. Liu W. Li X. Panebianco D. Mangin E. Morrison D. McCrea J. Wagner J.A. Troyer M.D. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J. Psychopharmacol. 2015 29 11 1159 1169 10.1177/0269881115609015 26464455
    [Google Scholar]
  40. Wrishko R.E. McCrea J.B. Yee K.L. Liu W. Panebianco D. Mangin E. Chakravarthy M. Martinez-Cantarin M.P. Kraft W.K. Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: Two phase I, open-label, fixed-sequence trials in healthy subjects. Clin. Drug Investig. 2019 39 5 441 451 10.1007/s40261‑019‑00764‑x 30810914
    [Google Scholar]
  41. Kuriyama A. Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med. Rev. 2017 35 1 7 10.1016/j.smrv.2016.09.004 28365447
    [Google Scholar]
  42. Yee K.L. McCrea J. Panebianco D. Liu W. Lewis N. Cabalu T. Ramael S. Wrishko R.E. Safety, tolerability, and pharmacokinetics of suvorexant: A randomized rising-dose trial in healthy men. Clin. Drug Investig. 2018 38 7 631 638 10.1007/s40261‑018‑0650‑4 29705869
    [Google Scholar]
  43. Earl D.C. Tyle v.K.M. New pharmacologic agents for insomnia and hypersomnia. Curr. Opin. Pulm. Med. 2020 26 6 629 633 10.1097/MCP.0000000000000722 32890017
    [Google Scholar]
  44. Hahn M. Pharmacology. InNeuroPsychopharmacotherapy Cham: Springer International Publishing. 2022 2281 2309
    [Google Scholar]
  45. Sun H. Kennedy W.P. Wilbraham D. Lewis N. Calder N. Li X. Ma J. Yee K.L. Ermlich S. Mangin E. Lines C. Rosen L. Chodakewitz J. Murphy G.M. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013 36 2 259 267 10.5665/sleep.2386 23372274
    [Google Scholar]
  46. Gatfield J. Brisbare-Roch C. Jenck F. Boss C. Orexin receptor antagonists: A new concept in CNS disorders? ChemMedChem 2010 5 8 1197 1214 10.1002/cmdc.201000132 20544785
    [Google Scholar]
  47. Winrow C.J. Gotter A.L. Cox C.D. Doran S.M. Tannenbaum P.L. Breslin M.J. Garson S.L. Fox S.V. Harrell C.M. Stevens J. Reiss D.R. Cui D. Coleman P.J. Renger J.J. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogenet. 2011 25 1-2 52 61 10.3109/01677063.2011.566953 21473737
    [Google Scholar]
  48. Sun H. Kennedy D. Lewis N. Laethem T. Yee K. Li X. Hoon J. Bortel V.L. Rosen L. Chodakewitz J. Wagner J. The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305); a dual orexin receptor antagonist, in healthy male subjects. Ann. Meet. Amer. Soc. Clin. Pharm. Ther. 2012 91 suppl. 1 S29 S29
    [Google Scholar]
  49. Ma J. Svetnik V. Snyder E. Lines C. Roth T. Herring W.J. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014 37 10 1609 1619 10.5665/sleep.4068 25197807
    [Google Scholar]
  50. Rocha R.B. Bomtempo F.F. Nager G.B. Cenci G.I. Telles J.P.M. Dual orexin receptor antagonists for the treatment of insomnia: Systematic review and network meta-analysis. Arq. Neuropsiquiatr. 2023 81 5 475 483 10.1055/s‑0043‑1768667 37257468
    [Google Scholar]
  51. Crescenzo D.F. D’Alò G.L. Ostinelli E.G. Ciabattini M. Franco D.V. Watanabe N. Kurtulmus A. Tomlinson A. Mitrova Z. Foti F. Giovane D.C. Quested D.J. Cowen P.J. Barbui C. Amato L. Efthimiou O. Cipriani A. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis. Lancet 2022 400 10347 170 184 10.1016/S0140‑6736(22)00878‑9 35843245
    [Google Scholar]
  52. Koopmans I. Geerse D. Ridder d.L. Roerdink M. Juachon M.J. Muehlan C. Dingemanse J. Gerven v.J. Groeneveld G.J. Zuiker R. The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clin. Transl. Sci. 2024 17 7 e13875 10.1111/cts.13875 38978326
    [Google Scholar]
  53. Zeitzer J.M. Joyce D.S. McBean A. Quevedo Y.L. Hernandez B. Holty J.E. Effect of suvorexant vs placebo on total daytime sleep hours in shift workers: A randomized clinical trial. JAMA Netw. Open 2020 3 6 e206614 10.1001/jamanetworkopen.2020.6614 32484552
    [Google Scholar]
  54. Khan H. Garg A. Yasmeen Agarwal N.B. Yadav D.K. Khan A.M. Hussain S. Zolpidem use and risk of suicide: A systematic review and meta-analysis. Psychiatry Res. 2022 316 114777 10.1016/j.psychres.2022.114777 35985088
    [Google Scholar]
  55. Griffin C.E. III Kaye A.M. Bueno F.R. Kaye A.D. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 13 2 214 223 23789008
    [Google Scholar]
  56. Brandt J. Leong C. Benzodiazepines and Z-drugs: An updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 2017 17 4 493 507 10.1007/s40268‑017‑0207‑7 28865038
    [Google Scholar]
  57. Janto K. Prichard J.R. Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J. Clin. Sleep Med. 2018 14 8 1399 1408 10.5664/jcsm.7282 30092886
    [Google Scholar]
  58. Etori K. Saito Y.C. Tsujino N. Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front. Neurosci. 2014 8 8 10.3389/fnins.2014.00008 24550770
    [Google Scholar]
  59. Dugovic C. Shelton J.E. Aluisio L.E. Fraser I.C. Jiang X. Sutton S.W. Bonaventure P. Yun S. Li X. Lord B. Dvorak C.A. Carruthers N.I. Lovenberg T.W. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 2009 330 1 142 151 10.1124/jpet.109.152009 19363060
    [Google Scholar]
  60. Han A.H. Burroughs C.R. Falgoust E.P. Hasoon J. Hunt G. Kakazu J. Lee T. Kaye A.M. Kaye A.D. Ganti L. Suvorexant, a novel dual orexin receptor antagonist, for the management of insomnia. Health Psychol. Res. 2023 10 5 67898 10.52965/001c.67898 36726477
    [Google Scholar]
  61. Xue T. Wu X. Chen S. Yang Y. Yan Z. Song Z. Zhang W. Zhang J. Chen Z. Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med. Rev. 2022 61 101573 10.1016/j.smrv.2021.101573 34902823
    [Google Scholar]
  62. Snyder E. Ma J. Svetnik V. Connor K.M. Lines C. Michelson D. Herring W.J. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: Analysis of pooled phase 3 data. Sleep Med. 2016 19 93 100 10.1016/j.sleep.2015.10.007 27198953
    [Google Scholar]
  63. Betschart C. Hintermann S. Behnke D. Cotesta S. Fendt M. Gee C.E. Jacobson L.H. Laue G. Ofner S. Chaudhari V. Badiger S. Pandit C. Wagner J. Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J. Med. Chem. 2013 56 19 7590 7607 10.1021/jm4007627 23964859
    [Google Scholar]
  64. Levinsohn E.A. Radhakrishnan V. Euting H. Kaplan G.B. Pharmacological management of sleep–wake disturbances in delirium. J. Clin. Pharmacol. 2024 1 6 Online ahead of print. 10.1002/jcph.6151
    [Google Scholar]
  65. Jha Divya Garg Aakriti Khan Mohd Ashif Effects of orexin receptor antagonist on cognitive function in adults: Asystematic review. Curr. Drug Ther. 2024 19 3 e040424228625 10.2174/0115748855292051240327084430
    [Google Scholar]
  66. Mieno Y. Hayashi M. Souma T. Horiguchi T. Niwa Y. Fujita S. Fukumoto J. Hosoda N. Imaizumi K. The effect of the initial administration of suvorexant on severe sleep apnea syndrome. Sleep Biol. Rhythms 2024 1 9 10.1007/s41105‑024‑00548‑7
    [Google Scholar]
  67. Callander G.E. Olorunda M. Monna D. Schuepbach E. Langenegger D. Betschart C. Hintermann S. Behnke D. Cotesta S. Fendt M. Laue G. Ofner S. Briard E. Gee C.E. Jacobson L.H. Hoyer D. Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors. Front. Neurosci. 2013 7 230 10.3389/fnins.2013.00230 24376396
    [Google Scholar]
  68. Jacobson L.H. Chen S. Mir S. Hoyer D. Orexin OX 2 receptor antagonists as sleep aids. Behavioral Neuroscience of Orexin/Hypocretin 2017 105 136
    [Google Scholar]
  69. Mang G.M. Dürst T. Bürki H. Imobersteg S. Abramowski D. Schuepbach E. Hoyer D. Fendt M. Gee C.E. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012 35 12 1625 1635 10.5665/sleep.2232 23204605
    [Google Scholar]
  70. Chen L. McKenna J.T. Bolortuya Y. Winston S. Thakkar M.M. Basheer R. Brown R.E. McCarley R.W. Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. Eur. J. Neurosci. 2010 32 9 1528 1536 10.1111/j.1460‑9568.2010.07401.x 21089218
    [Google Scholar]
  71. Hoyer D. Dürst T. Fendt M. Jacobson L.H. Betschart C. Hintermann S. Behnke D. Cotesta S. Laue G. Ofner S. Legangneux E. Gee C.E. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front. Neurosci. 2013 7 235 10.3389/fnins.2013.00235 24368893
    [Google Scholar]
/content/journals/cds/10.2174/0115748863337982250212111648
Loading
Efficacy and Safety Profile of Suvorexant for the Treatment of Insomnia
Bentham Science Publishers ; https://doi.org/10.2174/0115748863337982250212111648
/content/journals/cds/10.2174/0115748863337982250212111648
/content/journals/cds/10.2174/0115748863337982250212111648
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: suvorexant ; dual orexin receptor antagonists ; Insomnia ; MK-4305 ; belsomra

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test